nodes	percent_of_prediction	percent_of_DWPC	metapath
Paroxetine—CHRM2—Dimenhydrinate—allergic rhinitis	0.0764	0.108	CbGbCtD
Paroxetine—CHRM3—Cyproheptadine—allergic rhinitis	0.0614	0.087	CbGbCtD
Paroxetine—SLC6A2—Cyproheptadine—allergic rhinitis	0.0598	0.0849	CbGbCtD
Paroxetine—HTR2A—Cyproheptadine—allergic rhinitis	0.054	0.0765	CbGbCtD
Paroxetine—CHRM1—Cyproheptadine—allergic rhinitis	0.0534	0.0757	CbGbCtD
Paroxetine—CHRM2—Cyproheptadine—allergic rhinitis	0.0492	0.0698	CbGbCtD
Paroxetine—CHRM2—Diphenhydramine—allergic rhinitis	0.0373	0.0529	CbGbCtD
Paroxetine—CYP2B6—Diphenhydramine—allergic rhinitis	0.0281	0.0399	CbGbCtD
Paroxetine—CYP2C9—Desloratadine—allergic rhinitis	0.0259	0.0367	CbGbCtD
Paroxetine—ABCB1—Desloratadine—allergic rhinitis	0.0251	0.0356	CbGbCtD
Paroxetine—CYP2D6—Desloratadine—allergic rhinitis	0.0237	0.0336	CbGbCtD
Paroxetine—CYP2C8—Montelukast—allergic rhinitis	0.0213	0.0302	CbGbCtD
Paroxetine—CYP2C8—Loratadine—allergic rhinitis	0.0213	0.0302	CbGbCtD
Paroxetine—CYP2C9—Montelukast—allergic rhinitis	0.0149	0.0211	CbGbCtD
Paroxetine—CYP2C9—Loratadine—allergic rhinitis	0.0149	0.0211	CbGbCtD
Paroxetine—CYP2C9—Diphenhydramine—allergic rhinitis	0.0149	0.0211	CbGbCtD
Paroxetine—ABCB1—Loratadine—allergic rhinitis	0.0144	0.0205	CbGbCtD
Paroxetine—CYP2D6—Loratadine—allergic rhinitis	0.0136	0.0193	CbGbCtD
Paroxetine—CYP2D6—Diphenhydramine—allergic rhinitis	0.0136	0.0193	CbGbCtD
Paroxetine—ABCB1—Methylprednisolone—allergic rhinitis	0.0132	0.0187	CbGbCtD
Paroxetine—CYP2C8—Hydrocortisone—allergic rhinitis	0.0119	0.0168	CbGbCtD
Paroxetine—CYP2B6—Dexamethasone—allergic rhinitis	0.00974	0.0138	CbGbCtD
Paroxetine—ABCB1—Betamethasone—allergic rhinitis	0.00858	0.0122	CbGbCtD
Paroxetine—ABCB1—Prednisolone—allergic rhinitis	0.00847	0.012	CbGbCtD
Paroxetine—ABCB1—Hydrocortisone—allergic rhinitis	0.00803	0.0114	CbGbCtD
Paroxetine—CYP2C8—Dexamethasone—allergic rhinitis	0.00738	0.0105	CbGbCtD
Paroxetine—TACR1—Tachykinin receptors bind tachykinins—TAC1—allergic rhinitis	0.00572	0.208	CbGpPWpGaD
Paroxetine—CYP2C9—Dexamethasone—allergic rhinitis	0.00514	0.00729	CbGbCtD
Paroxetine—ABCB1—Dexamethasone—allergic rhinitis	0.00499	0.00708	CbGbCtD
Paroxetine—CYP2D6—Dexamethasone—allergic rhinitis	0.0047	0.00667	CbGbCtD
Paroxetine—SLC6A2—autonomic nervous system—allergic rhinitis	0.00239	0.126	CbGeAlD
Paroxetine—TACR1—respiratory system—allergic rhinitis	0.00152	0.0797	CbGeAlD
Paroxetine—HTR2A—autonomic nervous system—allergic rhinitis	0.00144	0.0755	CbGeAlD
Paroxetine—CHRM3—exocrine gland—allergic rhinitis	0.0012	0.0629	CbGeAlD
Paroxetine—TACR1—trachea—allergic rhinitis	0.00112	0.0589	CbGeAlD
Paroxetine—CHRM5—eye—allergic rhinitis	0.00102	0.0535	CbGeAlD
Paroxetine—CHRM5—epithelium—allergic rhinitis	0.000932	0.0489	CbGeAlD
Paroxetine—CHRM5—skin of body—allergic rhinitis	0.000886	0.0465	CbGeAlD
Paroxetine—TACR1—lung—allergic rhinitis	0.000806	0.0423	CbGeAlD
Paroxetine—SLC6A3—respiratory system—allergic rhinitis	0.000763	0.0401	CbGeAlD
Paroxetine—SLC6A4—respiratory system—allergic rhinitis	0.000699	0.0367	CbGeAlD
Paroxetine—SLC6A2—respiratory system—allergic rhinitis	0.000616	0.0323	CbGeAlD
Paroxetine—CHRM1—trachea—allergic rhinitis	0.000515	0.027	CbGeAlD
Paroxetine—CYP2B6—respiratory system—allergic rhinitis	0.000454	0.0238	CbGeAlD
Paroxetine—TACR1—G alpha (q) signalling events—CYSLTR1—allergic rhinitis	0.00045	0.0163	CbGpPWpGaD
Paroxetine—TACR1—Peptide ligand-binding receptors—CCL11—allergic rhinitis	0.000429	0.0156	CbGpPWpGaD
Paroxetine—SLC6A3—lung—allergic rhinitis	0.000405	0.0213	CbGeAlD
Paroxetine—TACR1—Gastrin-CREB signalling pathway via PKC and MAPK—CYSLTR1—allergic rhinitis	0.000403	0.0146	CbGpPWpGaD
Paroxetine—TACR1—SIDS Susceptibility Pathways—IL13—allergic rhinitis	0.000397	0.0144	CbGpPWpGaD
Paroxetine—TACR1—Class A/1 (Rhodopsin-like receptors)—PTGDR2—allergic rhinitis	0.00038	0.0138	CbGpPWpGaD
Paroxetine—CYP2B6—bronchus—allergic rhinitis	0.000373	0.0196	CbGeAlD
Paroxetine—SLC6A4—lung—allergic rhinitis	0.000371	0.0195	CbGeAlD
Paroxetine—HTR2A—respiratory system—allergic rhinitis	0.00037	0.0194	CbGeAlD
Paroxetine—CHRM1—lung—allergic rhinitis	0.00037	0.0194	CbGeAlD
Paroxetine—TACR1—SIDS Susceptibility Pathways—TAC1—allergic rhinitis	0.000365	0.0133	CbGpPWpGaD
Paroxetine—CYP2B6—skin of body—allergic rhinitis	0.000361	0.0189	CbGeAlD
Paroxetine—HTR2A—eye—allergic rhinitis	0.000338	0.0178	CbGeAlD
Paroxetine—SLC6A2—lung—allergic rhinitis	0.000327	0.0172	CbGeAlD
Paroxetine—TACR1—G alpha (q) signalling events—TAC1—allergic rhinitis	0.000316	0.0115	CbGpPWpGaD
Paroxetine—TACR1—Peptide ligand-binding receptors—TAC1—allergic rhinitis	0.000312	0.0113	CbGpPWpGaD
Paroxetine—HTR2A—epithelium—allergic rhinitis	0.000309	0.0162	CbGeAlD
Paroxetine—TACR1—Spinal Cord Injury—IL4—allergic rhinitis	0.000302	0.011	CbGpPWpGaD
Paroxetine—TACR1—Class A/1 (Rhodopsin-like receptors)—CYSLTR1—allergic rhinitis	0.000298	0.0108	CbGpPWpGaD
Paroxetine—TACR1—GPCR ligand binding—PTGDR2—allergic rhinitis	0.000289	0.0105	CbGpPWpGaD
Paroxetine—TACR1—Class A/1 (Rhodopsin-like receptors)—CCL11—allergic rhinitis	0.000288	0.0105	CbGpPWpGaD
Paroxetine—TACR1—Gastrin-CREB signalling pathway via PKC and MAPK—TAC1—allergic rhinitis	0.000282	0.0103	CbGpPWpGaD
Paroxetine—HTR2A—trachea—allergic rhinitis	0.000273	0.0144	CbGeAlD
Paroxetine—TACR1—SIDS Susceptibility Pathways—IL10—allergic rhinitis	0.000248	0.00901	CbGpPWpGaD
Paroxetine—ABCB1—respiratory system—allergic rhinitis	0.000242	0.0127	CbGeAlD
Paroxetine—CYP2B6—lung—allergic rhinitis	0.000241	0.0126	CbGeAlD
Paroxetine—TACR1—Spinal Cord Injury—ICAM1—allergic rhinitis	0.00024	0.00871	CbGpPWpGaD
Paroxetine—TACR1—GPCR ligand binding—CYSLTR1—allergic rhinitis	0.000227	0.00824	CbGpPWpGaD
Paroxetine—CHRM4—G alpha (i) signalling events—PTGDR2—allergic rhinitis	0.000219	0.00797	CbGpPWpGaD
Paroxetine—TACR1—GPCR ligand binding—CCL11—allergic rhinitis	0.000219	0.00796	CbGpPWpGaD
Paroxetine—TACR1—Class A/1 (Rhodopsin-like receptors)—TAC1—allergic rhinitis	0.000209	0.0076	CbGpPWpGaD
Paroxetine—SLC6A4—SIDS Susceptibility Pathways—IL13—allergic rhinitis	0.000205	0.00745	CbGpPWpGaD
Paroxetine—CHRM4—GPCRs, Class A Rhodopsin-like—PTGDR2—allergic rhinitis	0.000204	0.00739	CbGpPWpGaD
Paroxetine—ABCB1—epithelium—allergic rhinitis	0.000203	0.0106	CbGeAlD
Paroxetine—CHRM5—G alpha (q) signalling events—CYSLTR1—allergic rhinitis	0.000198	0.00719	CbGpPWpGaD
Paroxetine—HTR2A—lung—allergic rhinitis	0.000196	0.0103	CbGeAlD
Paroxetine—CHRM5—GPCRs, Class A Rhodopsin-like—PTGDR2—allergic rhinitis	0.000195	0.00708	CbGpPWpGaD
Paroxetine—SLC6A4—SIDS Susceptibility Pathways—TAC1—allergic rhinitis	0.000189	0.00686	CbGpPWpGaD
Paroxetine—ABCB1—trachea—allergic rhinitis	0.000179	0.00941	CbGeAlD
Paroxetine—CHRM5—Gastrin-CREB signalling pathway via PKC and MAPK—CYSLTR1—allergic rhinitis	0.000177	0.00643	CbGpPWpGaD
Paroxetine—CHRM4—Class A/1 (Rhodopsin-like receptors)—PTGDR2—allergic rhinitis	0.000174	0.00634	CbGpPWpGaD
Paroxetine—CHRM5—Class A/1 (Rhodopsin-like receptors)—PTGDR2—allergic rhinitis	0.000167	0.00607	CbGpPWpGaD
Paroxetine—TACR1—GPCR downstream signaling—PTGDR2—allergic rhinitis	0.000163	0.00594	CbGpPWpGaD
Paroxetine—CHRM4—GPCRs, Class A Rhodopsin-like—CYSLTR1—allergic rhinitis	0.00016	0.0058	CbGpPWpGaD
Paroxetine—TACR1—GPCR ligand binding—TAC1—allergic rhinitis	0.000159	0.00579	CbGpPWpGaD
Paroxetine—ABCB1—Allograft Rejection—FOXP3—allergic rhinitis	0.000157	0.00568	CbGpPWpGaD
Paroxetine—CHRM5—GPCRs, Class A Rhodopsin-like—CYSLTR1—allergic rhinitis	0.000153	0.00556	CbGpPWpGaD
Paroxetine—SLC6A3—Dopaminergic Neurogenesis—TGFB1—allergic rhinitis	0.000149	0.00541	CbGpPWpGaD
Paroxetine—TACR1—Signaling by GPCR—PTGDR2—allergic rhinitis	0.000148	0.00539	CbGpPWpGaD
Paroxetine—CHRM2—G alpha (i) signalling events—PTGDR2—allergic rhinitis	0.000146	0.0053	CbGpPWpGaD
Paroxetine—ABCB1—Allograft Rejection—HLA-G—allergic rhinitis	0.000142	0.00516	CbGpPWpGaD
Paroxetine—HTR2A—G alpha (q) signalling events—CYSLTR1—allergic rhinitis	0.00014	0.00509	CbGpPWpGaD
Paroxetine—CHRM1—G alpha (q) signalling events—CYSLTR1—allergic rhinitis	0.000139	0.00506	CbGpPWpGaD
Paroxetine—CHRM3—G alpha (q) signalling events—CYSLTR1—allergic rhinitis	0.000139	0.00505	CbGpPWpGaD
Paroxetine—CHRM5—G alpha (q) signalling events—TAC1—allergic rhinitis	0.000139	0.00504	CbGpPWpGaD
Paroxetine—SLC6A4—Circadian rythm related genes—ADIPOQ—allergic rhinitis	0.000139	0.00504	CbGpPWpGaD
Paroxetine—HTR2A—GPCRs, Class A Rhodopsin-like—PTGDR2—allergic rhinitis	0.000138	0.00501	CbGpPWpGaD
Paroxetine—CHRM1—GPCRs, Class A Rhodopsin-like—PTGDR2—allergic rhinitis	0.000137	0.00499	CbGpPWpGaD
Paroxetine—CHRM4—Class A/1 (Rhodopsin-like receptors)—CYSLTR1—allergic rhinitis	0.000137	0.00497	CbGpPWpGaD
Paroxetine—CHRM3—GPCRs, Class A Rhodopsin-like—PTGDR2—allergic rhinitis	0.000137	0.00497	CbGpPWpGaD
Paroxetine—CHRM2—GPCRs, Class A Rhodopsin-like—PTGDR2—allergic rhinitis	0.000136	0.00492	CbGpPWpGaD
Paroxetine—ABCB1—Allograft Rejection—IL13—allergic rhinitis	0.000134	0.00486	CbGpPWpGaD
Paroxetine—CHRM4—GPCR ligand binding—PTGDR2—allergic rhinitis	0.000133	0.00482	CbGpPWpGaD
Paroxetine—CHRM4—Class A/1 (Rhodopsin-like receptors)—CCL11—allergic rhinitis	0.000132	0.0048	CbGpPWpGaD
Paroxetine—CHRM5—Class A/1 (Rhodopsin-like receptors)—CYSLTR1—allergic rhinitis	0.000131	0.00476	CbGpPWpGaD
Paroxetine—ABCB1—lung—allergic rhinitis	0.000129	0.00676	CbGeAlD
Paroxetine—SLC6A4—SIDS Susceptibility Pathways—IL10—allergic rhinitis	0.000128	0.00466	CbGpPWpGaD
Paroxetine—TACR1—GPCR downstream signaling—CYSLTR1—allergic rhinitis	0.000128	0.00466	CbGpPWpGaD
Paroxetine—CHRM5—GPCR ligand binding—PTGDR2—allergic rhinitis	0.000127	0.00462	CbGpPWpGaD
Paroxetine—CHRM5—Class A/1 (Rhodopsin-like receptors)—CCL11—allergic rhinitis	0.000127	0.0046	CbGpPWpGaD
Paroxetine—TACR1—Spinal Cord Injury—TGFB1—allergic rhinitis	0.000126	0.00459	CbGpPWpGaD
Paroxetine—HTR2A—Gastrin-CREB signalling pathway via PKC and MAPK—CYSLTR1—allergic rhinitis	0.000125	0.00455	CbGpPWpGaD
Paroxetine—CHRM1—Gastrin-CREB signalling pathway via PKC and MAPK—CYSLTR1—allergic rhinitis	0.000125	0.00453	CbGpPWpGaD
Paroxetine—CHRM3—Gastrin-CREB signalling pathway via PKC and MAPK—CYSLTR1—allergic rhinitis	0.000124	0.00451	CbGpPWpGaD
Paroxetine—CHRM5—Gastrin-CREB signalling pathway via PKC and MAPK—TAC1—allergic rhinitis	0.000124	0.00451	CbGpPWpGaD
Paroxetine—HTR2A—SIDS Susceptibility Pathways—IL13—allergic rhinitis	0.000123	0.00449	CbGpPWpGaD
Paroxetine—ABCB1—Allograft Rejection—IL17A—allergic rhinitis	0.000123	0.00448	CbGpPWpGaD
Paroxetine—TACR1—SIDS Susceptibility Pathways—NFKB1—allergic rhinitis	0.000121	0.00441	CbGpPWpGaD
Paroxetine—CHRM2—SIDS Susceptibility Pathways—IL13—allergic rhinitis	0.000121	0.0044	CbGpPWpGaD
Paroxetine—HTR2A—Class A/1 (Rhodopsin-like receptors)—PTGDR2—allergic rhinitis	0.000118	0.00429	CbGpPWpGaD
Paroxetine—CHRM1—Class A/1 (Rhodopsin-like receptors)—PTGDR2—allergic rhinitis	0.000118	0.00427	CbGpPWpGaD
Paroxetine—CHRM3—Class A/1 (Rhodopsin-like receptors)—PTGDR2—allergic rhinitis	0.000117	0.00426	CbGpPWpGaD
Paroxetine—TACR1—Signaling by GPCR—CYSLTR1—allergic rhinitis	0.000116	0.00423	CbGpPWpGaD
Paroxetine—CHRM2—Class A/1 (Rhodopsin-like receptors)—PTGDR2—allergic rhinitis	0.000116	0.00422	CbGpPWpGaD
Paroxetine—ABCB1—Allograft Rejection—IL5—allergic rhinitis	0.000115	0.00416	CbGpPWpGaD
Paroxetine—HTR2A—SIDS Susceptibility Pathways—TAC1—allergic rhinitis	0.000114	0.00413	CbGpPWpGaD
Paroxetine—TACR1—Signaling by GPCR—CCL11—allergic rhinitis	0.000113	0.00409	CbGpPWpGaD
Paroxetine—CHRM2—SIDS Susceptibility Pathways—TAC1—allergic rhinitis	0.000112	0.00405	CbGpPWpGaD
Paroxetine—HTR2A—GPCRs, Class A Rhodopsin-like—CYSLTR1—allergic rhinitis	0.000108	0.00393	CbGpPWpGaD
Paroxetine—CHRM1—GPCRs, Class A Rhodopsin-like—CYSLTR1—allergic rhinitis	0.000108	0.00391	CbGpPWpGaD
Paroxetine—CHRM3—GPCRs, Class A Rhodopsin-like—CYSLTR1—allergic rhinitis	0.000107	0.0039	CbGpPWpGaD
Paroxetine—CHRM2—GPCRs, Class A Rhodopsin-like—CYSLTR1—allergic rhinitis	0.000106	0.00386	CbGpPWpGaD
Paroxetine—CHRM4—GPCR ligand binding—CYSLTR1—allergic rhinitis	0.000104	0.00379	CbGpPWpGaD
Paroxetine—CHRM4—GPCR ligand binding—CCL11—allergic rhinitis	0.000101	0.00366	CbGpPWpGaD
Paroxetine—CHRM5—GPCR ligand binding—CYSLTR1—allergic rhinitis	9.98e-05	0.00363	CbGpPWpGaD
Paroxetine—HTR2A—G alpha (q) signalling events—TAC1—allergic rhinitis	9.83e-05	0.00357	CbGpPWpGaD
Paroxetine—CHRM1—G alpha (q) signalling events—TAC1—allergic rhinitis	9.78e-05	0.00355	CbGpPWpGaD
Paroxetine—CHRM3—G alpha (q) signalling events—TAC1—allergic rhinitis	9.75e-05	0.00354	CbGpPWpGaD
Paroxetine—CHRM5—GPCR ligand binding—CCL11—allergic rhinitis	9.64e-05	0.0035	CbGpPWpGaD
Paroxetine—CHRM4—Class A/1 (Rhodopsin-like receptors)—TAC1—allergic rhinitis	9.6e-05	0.00349	CbGpPWpGaD
Paroxetine—ABCB1—HIF-1-alpha transcription factor network—SMAD3—allergic rhinitis	9.31e-05	0.00338	CbGpPWpGaD
Paroxetine—HTR2A—Class A/1 (Rhodopsin-like receptors)—CYSLTR1—allergic rhinitis	9.28e-05	0.00337	CbGpPWpGaD
Paroxetine—CHRM1—Class A/1 (Rhodopsin-like receptors)—CYSLTR1—allergic rhinitis	9.23e-05	0.00335	CbGpPWpGaD
Paroxetine—CHRM3—Class A/1 (Rhodopsin-like receptors)—CYSLTR1—allergic rhinitis	9.2e-05	0.00334	CbGpPWpGaD
Paroxetine—CHRM5—Class A/1 (Rhodopsin-like receptors)—TAC1—allergic rhinitis	9.2e-05	0.00334	CbGpPWpGaD
Paroxetine—CHRM2—Class A/1 (Rhodopsin-like receptors)—CYSLTR1—allergic rhinitis	9.11e-05	0.00331	CbGpPWpGaD
Paroxetine—HTR2A—GPCR ligand binding—PTGDR2—allergic rhinitis	9e-05	0.00327	CbGpPWpGaD
Paroxetine—TACR1—GPCR downstream signaling—TAC1—allergic rhinitis	9e-05	0.00327	CbGpPWpGaD
Paroxetine—HTR2A—Class A/1 (Rhodopsin-like receptors)—CCL11—allergic rhinitis	8.96e-05	0.00325	CbGpPWpGaD
Paroxetine—CHRM1—GPCR ligand binding—PTGDR2—allergic rhinitis	8.96e-05	0.00325	CbGpPWpGaD
Paroxetine—CHRM3—GPCR ligand binding—PTGDR2—allergic rhinitis	8.93e-05	0.00324	CbGpPWpGaD
Paroxetine—CHRM1—Class A/1 (Rhodopsin-like receptors)—CCL11—allergic rhinitis	8.91e-05	0.00324	CbGpPWpGaD
Paroxetine—CHRM3—Class A/1 (Rhodopsin-like receptors)—CCL11—allergic rhinitis	8.88e-05	0.00323	CbGpPWpGaD
Paroxetine—ABCB1—Allograft Rejection—HLA-DQB1—allergic rhinitis	8.87e-05	0.00322	CbGpPWpGaD
Paroxetine—CHRM2—GPCR ligand binding—PTGDR2—allergic rhinitis	8.84e-05	0.00321	CbGpPWpGaD
Paroxetine—CHRM2—Class A/1 (Rhodopsin-like receptors)—CCL11—allergic rhinitis	8.8e-05	0.0032	CbGpPWpGaD
Paroxetine—HTR2A—Gastrin-CREB signalling pathway via PKC and MAPK—TAC1—allergic rhinitis	8.79e-05	0.00319	CbGpPWpGaD
Paroxetine—TACR1—Signaling Pathways—PTGDR2—allergic rhinitis	8.77e-05	0.00319	CbGpPWpGaD
Paroxetine—CHRM1—Gastrin-CREB signalling pathway via PKC and MAPK—TAC1—allergic rhinitis	8.75e-05	0.00318	CbGpPWpGaD
Paroxetine—CHRM3—Gastrin-CREB signalling pathway via PKC and MAPK—TAC1—allergic rhinitis	8.72e-05	0.00317	CbGpPWpGaD
Paroxetine—CYP2D6—Melatonin metabolism and effects—NFKB1—allergic rhinitis	8.61e-05	0.00313	CbGpPWpGaD
Paroxetine—ABCB1—Allograft Rejection—IL10—allergic rhinitis	8.38e-05	0.00304	CbGpPWpGaD
Paroxetine—TACR1—GPCR downstream signaling—IL5—allergic rhinitis	8.37e-05	0.00304	CbGpPWpGaD
Paroxetine—CHRM1—Circadian rythm related genes—ADIPOQ—allergic rhinitis	8.31e-05	0.00302	CbGpPWpGaD
Paroxetine—TACR1—Signaling by GPCR—TAC1—allergic rhinitis	8.17e-05	0.00297	CbGpPWpGaD
Paroxetine—ABCB1—Allograft Rejection—IL4—allergic rhinitis	8.15e-05	0.00296	CbGpPWpGaD
Paroxetine—HTR2A—SIDS Susceptibility Pathways—IL10—allergic rhinitis	7.73e-05	0.00281	CbGpPWpGaD
Paroxetine—TACR1—Signaling by GPCR—IL5—allergic rhinitis	7.6e-05	0.00276	CbGpPWpGaD
Paroxetine—CHRM2—SIDS Susceptibility Pathways—IL10—allergic rhinitis	7.59e-05	0.00276	CbGpPWpGaD
Paroxetine—CHRM4—GPCR downstream signaling—PTGDR2—allergic rhinitis	7.51e-05	0.00273	CbGpPWpGaD
Paroxetine—CHRM4—GPCR ligand binding—TAC1—allergic rhinitis	7.31e-05	0.00266	CbGpPWpGaD
Paroxetine—CHRM5—GPCR downstream signaling—PTGDR2—allergic rhinitis	7.19e-05	0.00261	CbGpPWpGaD
Paroxetine—HTR2A—GPCR ligand binding—CYSLTR1—allergic rhinitis	7.07e-05	0.00257	CbGpPWpGaD
Paroxetine—CHRM1—GPCR ligand binding—CYSLTR1—allergic rhinitis	7.03e-05	0.00255	CbGpPWpGaD
Paroxetine—CHRM3—GPCR ligand binding—CYSLTR1—allergic rhinitis	7.01e-05	0.00254	CbGpPWpGaD
Paroxetine—CHRM5—GPCR ligand binding—TAC1—allergic rhinitis	7e-05	0.00254	CbGpPWpGaD
Paroxetine—CHRM2—GPCR ligand binding—CYSLTR1—allergic rhinitis	6.94e-05	0.00252	CbGpPWpGaD
Paroxetine—TACR1—Signaling Pathways—CYSLTR1—allergic rhinitis	6.88e-05	0.0025	CbGpPWpGaD
Paroxetine—HTR2A—GPCR ligand binding—CCL11—allergic rhinitis	6.82e-05	0.00248	CbGpPWpGaD
Paroxetine—CHRM4—Signaling by GPCR—PTGDR2—allergic rhinitis	6.82e-05	0.00248	CbGpPWpGaD
Paroxetine—CHRM1—GPCR ligand binding—CCL11—allergic rhinitis	6.79e-05	0.00247	CbGpPWpGaD
Paroxetine—CHRM3—GPCR ligand binding—CCL11—allergic rhinitis	6.77e-05	0.00246	CbGpPWpGaD
Paroxetine—CHRM2—GPCR ligand binding—CCL11—allergic rhinitis	6.7e-05	0.00243	CbGpPWpGaD
Paroxetine—TACR1—Signaling Pathways—CCL11—allergic rhinitis	6.65e-05	0.00241	CbGpPWpGaD
Paroxetine—CHRM5—Signaling by GPCR—PTGDR2—allergic rhinitis	6.53e-05	0.00237	CbGpPWpGaD
Paroxetine—HTR2A—Class A/1 (Rhodopsin-like receptors)—TAC1—allergic rhinitis	6.51e-05	0.00236	CbGpPWpGaD
Paroxetine—CHRM1—Class A/1 (Rhodopsin-like receptors)—TAC1—allergic rhinitis	6.48e-05	0.00235	CbGpPWpGaD
Paroxetine—CHRM3—Class A/1 (Rhodopsin-like receptors)—TAC1—allergic rhinitis	6.46e-05	0.00234	CbGpPWpGaD
Paroxetine—CHRM2—Class A/1 (Rhodopsin-like receptors)—TAC1—allergic rhinitis	6.39e-05	0.00232	CbGpPWpGaD
Paroxetine—SLC6A4—SIDS Susceptibility Pathways—NFKB1—allergic rhinitis	6.28e-05	0.00228	CbGpPWpGaD
Paroxetine—Headache—Montelukast—allergic rhinitis	6.08e-05	0.000245	CcSEcCtD
Paroxetine—Visual impairment—Dexamethasone—allergic rhinitis	6.08e-05	0.000245	CcSEcCtD
Paroxetine—Visual impairment—Betamethasone—allergic rhinitis	6.08e-05	0.000245	CcSEcCtD
Paroxetine—Mental disorder—Methylprednisolone—allergic rhinitis	6.08e-05	0.000245	CcSEcCtD
Paroxetine—Erythema—Triamcinolone—allergic rhinitis	6.05e-05	0.000244	CcSEcCtD
Paroxetine—Erythema—Methylprednisolone—allergic rhinitis	6.04e-05	0.000243	CcSEcCtD
Paroxetine—Malnutrition—Methylprednisolone—allergic rhinitis	6.04e-05	0.000243	CcSEcCtD
Paroxetine—Angioedema—Prednisolone—allergic rhinitis	6.01e-05	0.000242	CcSEcCtD
Paroxetine—Ill-defined disorder—Hydrocortisone—allergic rhinitis	5.96e-05	0.00024	CcSEcCtD
Paroxetine—Malaise—Prednisolone—allergic rhinitis	5.93e-05	0.000239	CcSEcCtD
Paroxetine—Dysgeusia—Triamcinolone—allergic rhinitis	5.93e-05	0.000239	CcSEcCtD
Paroxetine—Vertigo—Prednisolone—allergic rhinitis	5.91e-05	0.000238	CcSEcCtD
Paroxetine—Syncope—Prednisolone—allergic rhinitis	5.9e-05	0.000238	CcSEcCtD
Paroxetine—Eye disorder—Dexamethasone—allergic rhinitis	5.89e-05	0.000238	CcSEcCtD
Paroxetine—Eye disorder—Betamethasone—allergic rhinitis	5.89e-05	0.000238	CcSEcCtD
Paroxetine—CHRM4—GPCR downstream signaling—CYSLTR1—allergic rhinitis	5.89e-05	0.00214	CbGpPWpGaD
Paroxetine—Angioedema—Hydrocortisone—allergic rhinitis	5.87e-05	0.000237	CcSEcCtD
Paroxetine—Back pain—Triamcinolone—allergic rhinitis	5.85e-05	0.000236	CcSEcCtD
Paroxetine—Malaise—Hydrocortisone—allergic rhinitis	5.79e-05	0.000234	CcSEcCtD
Paroxetine—Loss of consciousness—Prednisolone—allergic rhinitis	5.78e-05	0.000233	CcSEcCtD
Paroxetine—Vertigo—Hydrocortisone—allergic rhinitis	5.77e-05	0.000233	CcSEcCtD
Paroxetine—Nausea—Montelukast—allergic rhinitis	5.77e-05	0.000233	CcSEcCtD
Paroxetine—Syncope—Hydrocortisone—allergic rhinitis	5.76e-05	0.000232	CcSEcCtD
Paroxetine—Angiopathy—Dexamethasone—allergic rhinitis	5.72e-05	0.000231	CcSEcCtD
Paroxetine—Angiopathy—Betamethasone—allergic rhinitis	5.72e-05	0.000231	CcSEcCtD
Paroxetine—Convulsion—Prednisolone—allergic rhinitis	5.7e-05	0.00023	CcSEcCtD
Paroxetine—Hypertension—Prednisolone—allergic rhinitis	5.68e-05	0.000229	CcSEcCtD
Paroxetine—Loss of consciousness—Hydrocortisone—allergic rhinitis	5.65e-05	0.000228	CcSEcCtD
Paroxetine—CHRM5—GPCR downstream signaling—CYSLTR1—allergic rhinitis	5.64e-05	0.00205	CbGpPWpGaD
Paroxetine—Arrhythmia—Betamethasone—allergic rhinitis	5.63e-05	0.000227	CcSEcCtD
Paroxetine—Arrhythmia—Dexamethasone—allergic rhinitis	5.63e-05	0.000227	CcSEcCtD
Paroxetine—Ill-defined disorder—Triamcinolone—allergic rhinitis	5.61e-05	0.000226	CcSEcCtD
Paroxetine—Ill-defined disorder—Methylprednisolone—allergic rhinitis	5.6e-05	0.000226	CcSEcCtD
Paroxetine—Alopecia—Dexamethasone—allergic rhinitis	5.57e-05	0.000225	CcSEcCtD
Paroxetine—Alopecia—Betamethasone—allergic rhinitis	5.57e-05	0.000225	CcSEcCtD
Paroxetine—Convulsion—Hydrocortisone—allergic rhinitis	5.57e-05	0.000224	CcSEcCtD
Paroxetine—Hypertension—Hydrocortisone—allergic rhinitis	5.55e-05	0.000224	CcSEcCtD
Paroxetine—Discomfort—Prednisolone—allergic rhinitis	5.53e-05	0.000223	CcSEcCtD
Paroxetine—Angioedema—Triamcinolone—allergic rhinitis	5.53e-05	0.000223	CcSEcCtD
Paroxetine—Angioedema—Methylprednisolone—allergic rhinitis	5.52e-05	0.000222	CcSEcCtD
Paroxetine—SLC6A4—NRF2 pathway—TGFB1—allergic rhinitis	5.52e-05	0.002	CbGpPWpGaD
Paroxetine—Erythema—Betamethasone—allergic rhinitis	5.49e-05	0.000221	CcSEcCtD
Paroxetine—Erythema—Dexamethasone—allergic rhinitis	5.49e-05	0.000221	CcSEcCtD
Paroxetine—Myalgia—Hydrocortisone—allergic rhinitis	5.47e-05	0.000221	CcSEcCtD
Paroxetine—Malaise—Triamcinolone—allergic rhinitis	5.46e-05	0.00022	CcSEcCtD
Paroxetine—Anxiety—Hydrocortisone—allergic rhinitis	5.45e-05	0.00022	CcSEcCtD
Paroxetine—Malaise—Methylprednisolone—allergic rhinitis	5.44e-05	0.000219	CcSEcCtD
Paroxetine—Vertigo—Triamcinolone—allergic rhinitis	5.44e-05	0.000219	CcSEcCtD
Paroxetine—Unspecified disorder of skin and subcutaneous tissue—Hydrocortisone—allergic rhinitis	5.43e-05	0.000219	CcSEcCtD
Paroxetine—Syncope—Triamcinolone—allergic rhinitis	5.43e-05	0.000219	CcSEcCtD
Paroxetine—Vertigo—Methylprednisolone—allergic rhinitis	5.42e-05	0.000219	CcSEcCtD
Paroxetine—Syncope—Methylprednisolone—allergic rhinitis	5.41e-05	0.000218	CcSEcCtD
Paroxetine—Discomfort—Hydrocortisone—allergic rhinitis	5.41e-05	0.000218	CcSEcCtD
Paroxetine—Anaphylactic shock—Prednisolone—allergic rhinitis	5.37e-05	0.000216	CcSEcCtD
Paroxetine—Oedema—Prednisolone—allergic rhinitis	5.37e-05	0.000216	CcSEcCtD
Paroxetine—CHRM4—Signaling by GPCR—CYSLTR1—allergic rhinitis	5.35e-05	0.00194	CbGpPWpGaD
Paroxetine—Loss of consciousness—Triamcinolone—allergic rhinitis	5.32e-05	0.000214	CcSEcCtD
Paroxetine—Loss of consciousness—Methylprednisolone—allergic rhinitis	5.31e-05	0.000214	CcSEcCtD
Paroxetine—Shock—Prednisolone—allergic rhinitis	5.28e-05	0.000213	CcSEcCtD
Paroxetine—Cough—Triamcinolone—allergic rhinitis	5.28e-05	0.000213	CcSEcCtD
Paroxetine—Oedema—Hydrocortisone—allergic rhinitis	5.24e-05	0.000211	CcSEcCtD
Paroxetine—Anaphylactic shock—Hydrocortisone—allergic rhinitis	5.24e-05	0.000211	CcSEcCtD
Paroxetine—Convulsion—Triamcinolone—allergic rhinitis	5.24e-05	0.000211	CcSEcCtD
Paroxetine—Tachycardia—Prednisolone—allergic rhinitis	5.24e-05	0.000211	CcSEcCtD
Paroxetine—Convulsion—Methylprednisolone—allergic rhinitis	5.23e-05	0.000211	CcSEcCtD
Paroxetine—Hypertension—Triamcinolone—allergic rhinitis	5.22e-05	0.000211	CcSEcCtD
Paroxetine—Hypertension—Methylprednisolone—allergic rhinitis	5.21e-05	0.00021	CcSEcCtD
Paroxetine—Infection—Hydrocortisone—allergic rhinitis	5.21e-05	0.00021	CcSEcCtD
Paroxetine—Hyperhidrosis—Prednisolone—allergic rhinitis	5.19e-05	0.000209	CcSEcCtD
Paroxetine—CHRM4—Signaling by GPCR—CCL11—allergic rhinitis	5.17e-05	0.00188	CbGpPWpGaD
Paroxetine—Shock—Hydrocortisone—allergic rhinitis	5.16e-05	0.000208	CcSEcCtD
Paroxetine—Myalgia—Triamcinolone—allergic rhinitis	5.15e-05	0.000208	CcSEcCtD
Paroxetine—Nervous system disorder—Hydrocortisone—allergic rhinitis	5.14e-05	0.000207	CcSEcCtD
Paroxetine—Myalgia—Methylprednisolone—allergic rhinitis	5.14e-05	0.000207	CcSEcCtD
Paroxetine—Arthralgia—Methylprednisolone—allergic rhinitis	5.14e-05	0.000207	CcSEcCtD
Paroxetine—CHRM5—Signaling by GPCR—CYSLTR1—allergic rhinitis	5.12e-05	0.00186	CbGpPWpGaD
Paroxetine—Anxiety—Methylprednisolone—allergic rhinitis	5.12e-05	0.000206	CcSEcCtD
Paroxetine—Tachycardia—Hydrocortisone—allergic rhinitis	5.12e-05	0.000206	CcSEcCtD
Paroxetine—Unspecified disorder of skin and subcutaneous tissue—Methylprednisolone—allergic rhinitis	5.1e-05	0.000206	CcSEcCtD
Paroxetine—Skin disorder—Hydrocortisone—allergic rhinitis	5.09e-05	0.000205	CcSEcCtD
Paroxetine—Ill-defined disorder—Betamethasone—allergic rhinitis	5.09e-05	0.000205	CcSEcCtD
Paroxetine—Ill-defined disorder—Dexamethasone—allergic rhinitis	5.09e-05	0.000205	CcSEcCtD
Paroxetine—Discomfort—Triamcinolone—allergic rhinitis	5.09e-05	0.000205	CcSEcCtD
Paroxetine—HTR2A—GPCR downstream signaling—PTGDR2—allergic rhinitis	5.09e-05	0.00185	CbGpPWpGaD
Paroxetine—Discomfort—Methylprednisolone—allergic rhinitis	5.08e-05	0.000205	CcSEcCtD
Paroxetine—Hyperhidrosis—Hydrocortisone—allergic rhinitis	5.07e-05	0.000204	CcSEcCtD
Paroxetine—CHRM1—GPCR downstream signaling—PTGDR2—allergic rhinitis	5.06e-05	0.00184	CbGpPWpGaD
Paroxetine—CHRM3—GPCR downstream signaling—PTGDR2—allergic rhinitis	5.05e-05	0.00183	CbGpPWpGaD
Paroxetine—Dry mouth—Triamcinolone—allergic rhinitis	5.04e-05	0.000203	CcSEcCtD
Paroxetine—Angioedema—Dexamethasone—allergic rhinitis	5.02e-05	0.000202	CcSEcCtD
Paroxetine—Angioedema—Betamethasone—allergic rhinitis	5.02e-05	0.000202	CcSEcCtD
Paroxetine—CHRM2—GPCR downstream signaling—PTGDR2—allergic rhinitis	5e-05	0.00181	CbGpPWpGaD
Paroxetine—Confusional state—Methylprednisolone—allergic rhinitis	4.97e-05	0.0002	CcSEcCtD
Paroxetine—HTR2A—GPCR ligand binding—TAC1—allergic rhinitis	4.96e-05	0.0018	CbGpPWpGaD
Paroxetine—Malaise—Dexamethasone—allergic rhinitis	4.95e-05	0.0002	CcSEcCtD
Paroxetine—Malaise—Betamethasone—allergic rhinitis	4.95e-05	0.0002	CcSEcCtD
Paroxetine—CHRM5—Signaling by GPCR—CCL11—allergic rhinitis	4.95e-05	0.0018	CbGpPWpGaD
Paroxetine—Anaphylactic shock—Triamcinolone—allergic rhinitis	4.94e-05	0.000199	CcSEcCtD
Paroxetine—Oedema—Triamcinolone—allergic rhinitis	4.94e-05	0.000199	CcSEcCtD
Paroxetine—Vertigo—Dexamethasone—allergic rhinitis	4.93e-05	0.000199	CcSEcCtD
Paroxetine—Vertigo—Betamethasone—allergic rhinitis	4.93e-05	0.000199	CcSEcCtD
Paroxetine—CHRM1—GPCR ligand binding—TAC1—allergic rhinitis	4.93e-05	0.00179	CbGpPWpGaD
Paroxetine—Anaphylactic shock—Methylprednisolone—allergic rhinitis	4.93e-05	0.000199	CcSEcCtD
Paroxetine—Syncope—Dexamethasone—allergic rhinitis	4.92e-05	0.000198	CcSEcCtD
Paroxetine—Syncope—Betamethasone—allergic rhinitis	4.92e-05	0.000198	CcSEcCtD
Paroxetine—CHRM3—GPCR ligand binding—TAC1—allergic rhinitis	4.92e-05	0.00179	CbGpPWpGaD
Paroxetine—Infection—Triamcinolone—allergic rhinitis	4.91e-05	0.000198	CcSEcCtD
Paroxetine—Hypotension—Hydrocortisone—allergic rhinitis	4.9e-05	0.000198	CcSEcCtD
Paroxetine—Infection—Methylprednisolone—allergic rhinitis	4.89e-05	0.000197	CcSEcCtD
Paroxetine—CHRM2—GPCR ligand binding—TAC1—allergic rhinitis	4.87e-05	0.00177	CbGpPWpGaD
Paroxetine—Shock—Triamcinolone—allergic rhinitis	4.86e-05	0.000196	CcSEcCtD
Paroxetine—Insomnia—Prednisolone—allergic rhinitis	4.86e-05	0.000196	CcSEcCtD
Paroxetine—Shock—Methylprednisolone—allergic rhinitis	4.85e-05	0.000195	CcSEcCtD
Paroxetine—Nervous system disorder—Methylprednisolone—allergic rhinitis	4.83e-05	0.000195	CcSEcCtD
Paroxetine—TACR1—Signaling Pathways—TAC1—allergic rhinitis	4.83e-05	0.00175	CbGpPWpGaD
Paroxetine—Loss of consciousness—Betamethasone—allergic rhinitis	4.83e-05	0.000194	CcSEcCtD
Paroxetine—Loss of consciousness—Dexamethasone—allergic rhinitis	4.83e-05	0.000194	CcSEcCtD
Paroxetine—Paraesthesia—Prednisolone—allergic rhinitis	4.82e-05	0.000194	CcSEcCtD
Paroxetine—Tachycardia—Triamcinolone—allergic rhinitis	4.82e-05	0.000194	CcSEcCtD
Paroxetine—Tachycardia—Methylprednisolone—allergic rhinitis	4.81e-05	0.000194	CcSEcCtD
Paroxetine—Skin disorder—Methylprednisolone—allergic rhinitis	4.79e-05	0.000193	CcSEcCtD
Paroxetine—Musculoskeletal discomfort—Hydrocortisone—allergic rhinitis	4.78e-05	0.000193	CcSEcCtD
Paroxetine—Hyperhidrosis—Triamcinolone—allergic rhinitis	4.77e-05	0.000192	CcSEcCtD
Paroxetine—Hyperhidrosis—Methylprednisolone—allergic rhinitis	4.76e-05	0.000192	CcSEcCtD
Paroxetine—Convulsion—Betamethasone—allergic rhinitis	4.76e-05	0.000192	CcSEcCtD
Paroxetine—Convulsion—Dexamethasone—allergic rhinitis	4.76e-05	0.000192	CcSEcCtD
Paroxetine—SLC6A2—NRF2 pathway—TGFB1—allergic rhinitis	4.74e-05	0.00172	CbGpPWpGaD
Paroxetine—Insomnia—Hydrocortisone—allergic rhinitis	4.74e-05	0.000191	CcSEcCtD
Paroxetine—Hypertension—Dexamethasone—allergic rhinitis	4.74e-05	0.000191	CcSEcCtD
Paroxetine—Hypertension—Betamethasone—allergic rhinitis	4.74e-05	0.000191	CcSEcCtD
Paroxetine—Paraesthesia—Hydrocortisone—allergic rhinitis	4.71e-05	0.00019	CcSEcCtD
Paroxetine—Myalgia—Betamethasone—allergic rhinitis	4.67e-05	0.000188	CcSEcCtD
Paroxetine—Myalgia—Dexamethasone—allergic rhinitis	4.67e-05	0.000188	CcSEcCtD
Paroxetine—Anxiety—Dexamethasone—allergic rhinitis	4.66e-05	0.000188	CcSEcCtD
Paroxetine—Anxiety—Betamethasone—allergic rhinitis	4.66e-05	0.000188	CcSEcCtD
Paroxetine—HTR2A—Signaling by GPCR—PTGDR2—allergic rhinitis	4.62e-05	0.00168	CbGpPWpGaD
Paroxetine—Discomfort—Dexamethasone—allergic rhinitis	4.62e-05	0.000186	CcSEcCtD
Paroxetine—Discomfort—Betamethasone—allergic rhinitis	4.62e-05	0.000186	CcSEcCtD
Paroxetine—Dyspepsia—Hydrocortisone—allergic rhinitis	4.62e-05	0.000186	CcSEcCtD
Paroxetine—Hypotension—Methylprednisolone—allergic rhinitis	4.6e-05	0.000186	CcSEcCtD
Paroxetine—CHRM1—Signaling by GPCR—PTGDR2—allergic rhinitis	4.6e-05	0.00167	CbGpPWpGaD
Paroxetine—Pain—Prednisolone—allergic rhinitis	4.59e-05	0.000185	CcSEcCtD
Paroxetine—CHRM3—Signaling by GPCR—PTGDR2—allergic rhinitis	4.58e-05	0.00166	CbGpPWpGaD
Paroxetine—Decreased appetite—Hydrocortisone—allergic rhinitis	4.56e-05	0.000184	CcSEcCtD
Paroxetine—CHRM2—Signaling by GPCR—PTGDR2—allergic rhinitis	4.54e-05	0.00165	CbGpPWpGaD
Paroxetine—Gastrointestinal disorder—Hydrocortisone—allergic rhinitis	4.53e-05	0.000182	CcSEcCtD
Paroxetine—Fatigue—Hydrocortisone—allergic rhinitis	4.52e-05	0.000182	CcSEcCtD
Paroxetine—Musculoskeletal discomfort—Triamcinolone—allergic rhinitis	4.5e-05	0.000181	CcSEcCtD
Paroxetine—TACR1—Signaling Pathways—IL5—allergic rhinitis	4.49e-05	0.00163	CbGpPWpGaD
Paroxetine—Musculoskeletal discomfort—Methylprednisolone—allergic rhinitis	4.49e-05	0.000181	CcSEcCtD
Paroxetine—Pain—Hydrocortisone—allergic rhinitis	4.48e-05	0.000181	CcSEcCtD
Paroxetine—Oedema—Dexamethasone—allergic rhinitis	4.48e-05	0.000181	CcSEcCtD
Paroxetine—Oedema—Betamethasone—allergic rhinitis	4.48e-05	0.000181	CcSEcCtD
Paroxetine—Anaphylactic shock—Dexamethasone—allergic rhinitis	4.48e-05	0.000181	CcSEcCtD
Paroxetine—Anaphylactic shock—Betamethasone—allergic rhinitis	4.48e-05	0.000181	CcSEcCtD
Paroxetine—Insomnia—Triamcinolone—allergic rhinitis	4.47e-05	0.00018	CcSEcCtD
Paroxetine—Insomnia—Methylprednisolone—allergic rhinitis	4.46e-05	0.00018	CcSEcCtD
Paroxetine—Infection—Dexamethasone—allergic rhinitis	4.45e-05	0.000179	CcSEcCtD
Paroxetine—Infection—Betamethasone—allergic rhinitis	4.45e-05	0.000179	CcSEcCtD
Paroxetine—Paraesthesia—Triamcinolone—allergic rhinitis	4.43e-05	0.000179	CcSEcCtD
Paroxetine—Feeling abnormal—Prednisolone—allergic rhinitis	4.42e-05	0.000178	CcSEcCtD
Paroxetine—Paraesthesia—Methylprednisolone—allergic rhinitis	4.42e-05	0.000178	CcSEcCtD
Paroxetine—Shock—Dexamethasone—allergic rhinitis	4.41e-05	0.000178	CcSEcCtD
Paroxetine—Shock—Betamethasone—allergic rhinitis	4.41e-05	0.000178	CcSEcCtD
Paroxetine—Dyspnoea—Triamcinolone—allergic rhinitis	4.4e-05	0.000177	CcSEcCtD
Paroxetine—Nervous system disorder—Dexamethasone—allergic rhinitis	4.39e-05	0.000177	CcSEcCtD
Paroxetine—Nervous system disorder—Betamethasone—allergic rhinitis	4.39e-05	0.000177	CcSEcCtD
Paroxetine—Thrombocytopenia—Dexamethasone—allergic rhinitis	4.39e-05	0.000177	CcSEcCtD
Paroxetine—Thrombocytopenia—Betamethasone—allergic rhinitis	4.39e-05	0.000177	CcSEcCtD
Paroxetine—Tachycardia—Dexamethasone—allergic rhinitis	4.37e-05	0.000176	CcSEcCtD
Paroxetine—Tachycardia—Betamethasone—allergic rhinitis	4.37e-05	0.000176	CcSEcCtD
Paroxetine—Dyspepsia—Triamcinolone—allergic rhinitis	4.35e-05	0.000175	CcSEcCtD
Paroxetine—Dyspepsia—Methylprednisolone—allergic rhinitis	4.34e-05	0.000175	CcSEcCtD
Paroxetine—Hyperhidrosis—Betamethasone—allergic rhinitis	4.33e-05	0.000175	CcSEcCtD
Paroxetine—Hyperhidrosis—Dexamethasone—allergic rhinitis	4.33e-05	0.000175	CcSEcCtD
Paroxetine—Feeling abnormal—Hydrocortisone—allergic rhinitis	4.32e-05	0.000174	CcSEcCtD
Paroxetine—Gastrointestinal pain—Hydrocortisone—allergic rhinitis	4.29e-05	0.000173	CcSEcCtD
Paroxetine—Urticaria—Prednisolone—allergic rhinitis	4.27e-05	0.000172	CcSEcCtD
Paroxetine—Fatigue—Triamcinolone—allergic rhinitis	4.26e-05	0.000172	CcSEcCtD
Paroxetine—Fatigue—Methylprednisolone—allergic rhinitis	4.25e-05	0.000171	CcSEcCtD
Paroxetine—Pain—Triamcinolone—allergic rhinitis	4.22e-05	0.00017	CcSEcCtD
Paroxetine—SLC6A3—NRF2 pathway—TGFB1—allergic rhinitis	4.2e-05	0.00153	CbGpPWpGaD
Paroxetine—Hypotension—Betamethasone—allergic rhinitis	4.19e-05	0.000169	CcSEcCtD
Paroxetine—Hypotension—Dexamethasone—allergic rhinitis	4.19e-05	0.000169	CcSEcCtD
Paroxetine—Urticaria—Hydrocortisone—allergic rhinitis	4.17e-05	0.000168	CcSEcCtD
Paroxetine—Abdominal pain—Hydrocortisone—allergic rhinitis	4.15e-05	0.000167	CcSEcCtD
Paroxetine—Body temperature increased—Hydrocortisone—allergic rhinitis	4.15e-05	0.000167	CcSEcCtD
Paroxetine—CHRM4—GPCR downstream signaling—TAC1—allergic rhinitis	4.13e-05	0.0015	CbGpPWpGaD
Paroxetine—Musculoskeletal discomfort—Dexamethasone—allergic rhinitis	4.08e-05	0.000165	CcSEcCtD
Paroxetine—Musculoskeletal discomfort—Betamethasone—allergic rhinitis	4.08e-05	0.000165	CcSEcCtD
Paroxetine—Feeling abnormal—Triamcinolone—allergic rhinitis	4.07e-05	0.000164	CcSEcCtD
Paroxetine—Feeling abnormal—Methylprednisolone—allergic rhinitis	4.06e-05	0.000164	CcSEcCtD
Paroxetine—Insomnia—Betamethasone—allergic rhinitis	4.05e-05	0.000163	CcSEcCtD
Paroxetine—Insomnia—Dexamethasone—allergic rhinitis	4.05e-05	0.000163	CcSEcCtD
Paroxetine—Gastrointestinal pain—Methylprednisolone—allergic rhinitis	4.03e-05	0.000162	CcSEcCtD
Paroxetine—CHRM4—Signaling Pathways—PTGDR2—allergic rhinitis	4.03e-05	0.00146	CbGpPWpGaD
Paroxetine—Paraesthesia—Dexamethasone—allergic rhinitis	4.02e-05	0.000162	CcSEcCtD
Paroxetine—Paraesthesia—Betamethasone—allergic rhinitis	4.02e-05	0.000162	CcSEcCtD
Paroxetine—HTR2A—GPCR downstream signaling—CYSLTR1—allergic rhinitis	3.99e-05	0.00145	CbGpPWpGaD
Paroxetine—CHRM1—GPCR downstream signaling—CYSLTR1—allergic rhinitis	3.97e-05	0.00144	CbGpPWpGaD
Paroxetine—CHRM3—GPCR downstream signaling—CYSLTR1—allergic rhinitis	3.96e-05	0.00144	CbGpPWpGaD
Paroxetine—CHRM5—GPCR downstream signaling—TAC1—allergic rhinitis	3.96e-05	0.00144	CbGpPWpGaD
Paroxetine—Hypersensitivity—Prednisolone—allergic rhinitis	3.96e-05	0.000159	CcSEcCtD
Paroxetine—Dyspepsia—Betamethasone—allergic rhinitis	3.94e-05	0.000159	CcSEcCtD
Paroxetine—Dyspepsia—Dexamethasone—allergic rhinitis	3.94e-05	0.000159	CcSEcCtD
Paroxetine—Urticaria—Triamcinolone—allergic rhinitis	3.92e-05	0.000158	CcSEcCtD
Paroxetine—CHRM2—GPCR downstream signaling—CYSLTR1—allergic rhinitis	3.92e-05	0.00142	CbGpPWpGaD
Paroxetine—Urticaria—Methylprednisolone—allergic rhinitis	3.91e-05	0.000158	CcSEcCtD
Paroxetine—Body temperature increased—Triamcinolone—allergic rhinitis	3.9e-05	0.000157	CcSEcCtD
Paroxetine—Abdominal pain—Methylprednisolone—allergic rhinitis	3.89e-05	0.000157	CcSEcCtD
Paroxetine—Decreased appetite—Betamethasone—allergic rhinitis	3.89e-05	0.000157	CcSEcCtD
Paroxetine—Decreased appetite—Dexamethasone—allergic rhinitis	3.89e-05	0.000157	CcSEcCtD
Paroxetine—Gastrointestinal disorder—Betamethasone—allergic rhinitis	3.87e-05	0.000156	CcSEcCtD
Paroxetine—Gastrointestinal disorder—Dexamethasone—allergic rhinitis	3.87e-05	0.000156	CcSEcCtD
Paroxetine—Hypersensitivity—Hydrocortisone—allergic rhinitis	3.86e-05	0.000156	CcSEcCtD
Paroxetine—Fatigue—Betamethasone—allergic rhinitis	3.86e-05	0.000156	CcSEcCtD
Paroxetine—Fatigue—Dexamethasone—allergic rhinitis	3.86e-05	0.000156	CcSEcCtD
Paroxetine—CHRM5—Signaling Pathways—PTGDR2—allergic rhinitis	3.86e-05	0.0014	CbGpPWpGaD
Paroxetine—CHRM4—GPCR downstream signaling—IL5—allergic rhinitis	3.84e-05	0.0014	CbGpPWpGaD
Paroxetine—Pain—Betamethasone—allergic rhinitis	3.83e-05	0.000154	CcSEcCtD
Paroxetine—Pain—Dexamethasone—allergic rhinitis	3.83e-05	0.000154	CcSEcCtD
Paroxetine—HTR2A—SIDS Susceptibility Pathways—NFKB1—allergic rhinitis	3.78e-05	0.00137	CbGpPWpGaD
Paroxetine—Asthenia—Hydrocortisone—allergic rhinitis	3.76e-05	0.000152	CcSEcCtD
Paroxetine—CHRM4—Signaling by GPCR—TAC1—allergic rhinitis	3.75e-05	0.00136	CbGpPWpGaD
Paroxetine—CHRM2—SIDS Susceptibility Pathways—NFKB1—allergic rhinitis	3.71e-05	0.00135	CbGpPWpGaD
Paroxetine—Pruritus—Hydrocortisone—allergic rhinitis	3.71e-05	0.00015	CcSEcCtD
Paroxetine—Feeling abnormal—Dexamethasone—allergic rhinitis	3.69e-05	0.000149	CcSEcCtD
Paroxetine—Feeling abnormal—Betamethasone—allergic rhinitis	3.69e-05	0.000149	CcSEcCtD
Paroxetine—CHRM5—GPCR downstream signaling—IL5—allergic rhinitis	3.68e-05	0.00134	CbGpPWpGaD
Paroxetine—Gastrointestinal pain—Betamethasone—allergic rhinitis	3.66e-05	0.000148	CcSEcCtD
Paroxetine—Gastrointestinal pain—Dexamethasone—allergic rhinitis	3.66e-05	0.000148	CcSEcCtD
Paroxetine—Hypersensitivity—Triamcinolone—allergic rhinitis	3.64e-05	0.000147	CcSEcCtD
Paroxetine—Hypersensitivity—Methylprednisolone—allergic rhinitis	3.63e-05	0.000146	CcSEcCtD
Paroxetine—HTR2A—Signaling by GPCR—CYSLTR1—allergic rhinitis	3.63e-05	0.00132	CbGpPWpGaD
Paroxetine—CHRM1—Signaling by GPCR—CYSLTR1—allergic rhinitis	3.61e-05	0.00131	CbGpPWpGaD
Paroxetine—CHRM3—Signaling by GPCR—CYSLTR1—allergic rhinitis	3.6e-05	0.00131	CbGpPWpGaD
Paroxetine—CHRM5—Signaling by GPCR—TAC1—allergic rhinitis	3.59e-05	0.00131	CbGpPWpGaD
Paroxetine—Diarrhoea—Hydrocortisone—allergic rhinitis	3.59e-05	0.000145	CcSEcCtD
Paroxetine—CHRM2—Signaling by GPCR—CYSLTR1—allergic rhinitis	3.56e-05	0.00129	CbGpPWpGaD
Paroxetine—Urticaria—Dexamethasone—allergic rhinitis	3.56e-05	0.000143	CcSEcCtD
Paroxetine—Urticaria—Betamethasone—allergic rhinitis	3.56e-05	0.000143	CcSEcCtD
Paroxetine—Dizziness—Prednisolone—allergic rhinitis	3.55e-05	0.000143	CcSEcCtD
Paroxetine—Asthenia—Triamcinolone—allergic rhinitis	3.54e-05	0.000143	CcSEcCtD
Paroxetine—Body temperature increased—Dexamethasone—allergic rhinitis	3.54e-05	0.000143	CcSEcCtD
Paroxetine—Abdominal pain—Betamethasone—allergic rhinitis	3.54e-05	0.000143	CcSEcCtD
Paroxetine—Body temperature increased—Betamethasone—allergic rhinitis	3.54e-05	0.000143	CcSEcCtD
Paroxetine—Abdominal pain—Dexamethasone—allergic rhinitis	3.54e-05	0.000143	CcSEcCtD
Paroxetine—Asthenia—Methylprednisolone—allergic rhinitis	3.54e-05	0.000142	CcSEcCtD
Paroxetine—HTR2A—Signaling by GPCR—CCL11—allergic rhinitis	3.5e-05	0.00127	CbGpPWpGaD
Paroxetine—Pruritus—Triamcinolone—allergic rhinitis	3.49e-05	0.000141	CcSEcCtD
Paroxetine—CHRM4—Signaling by GPCR—IL5—allergic rhinitis	3.49e-05	0.00127	CbGpPWpGaD
Paroxetine—Pruritus—Methylprednisolone—allergic rhinitis	3.49e-05	0.000141	CcSEcCtD
Paroxetine—CHRM1—Signaling by GPCR—CCL11—allergic rhinitis	3.48e-05	0.00127	CbGpPWpGaD
Paroxetine—CHRM3—Signaling by GPCR—CCL11—allergic rhinitis	3.47e-05	0.00126	CbGpPWpGaD
Paroxetine—Dizziness—Hydrocortisone—allergic rhinitis	3.47e-05	0.00014	CcSEcCtD
Paroxetine—CHRM2—Signaling by GPCR—CCL11—allergic rhinitis	3.44e-05	0.00125	CbGpPWpGaD
Paroxetine—ABCB1—Allograft Rejection—TGFB1—allergic rhinitis	3.41e-05	0.00124	CbGpPWpGaD
Paroxetine—Rash—Prednisolone—allergic rhinitis	3.39e-05	0.000136	CcSEcCtD
Paroxetine—Dermatitis—Prednisolone—allergic rhinitis	3.38e-05	0.000136	CcSEcCtD
Paroxetine—Diarrhoea—Methylprednisolone—allergic rhinitis	3.37e-05	0.000136	CcSEcCtD
Paroxetine—Headache—Prednisolone—allergic rhinitis	3.36e-05	0.000136	CcSEcCtD
Paroxetine—CHRM5—Signaling by GPCR—IL5—allergic rhinitis	3.34e-05	0.00121	CbGpPWpGaD
Paroxetine—Vomiting—Hydrocortisone—allergic rhinitis	3.33e-05	0.000134	CcSEcCtD
Paroxetine—Rash—Hydrocortisone—allergic rhinitis	3.31e-05	0.000133	CcSEcCtD
Paroxetine—Dermatitis—Hydrocortisone—allergic rhinitis	3.3e-05	0.000133	CcSEcCtD
Paroxetine—Headache—Hydrocortisone—allergic rhinitis	3.29e-05	0.000132	CcSEcCtD
Paroxetine—Dizziness—Triamcinolone—allergic rhinitis	3.27e-05	0.000132	CcSEcCtD
Paroxetine—Dizziness—Methylprednisolone—allergic rhinitis	3.26e-05	0.000131	CcSEcCtD
Paroxetine—Asthenia—Dexamethasone—allergic rhinitis	3.21e-05	0.00013	CcSEcCtD
Paroxetine—Asthenia—Betamethasone—allergic rhinitis	3.21e-05	0.00013	CcSEcCtD
Paroxetine—Nausea—Prednisolone—allergic rhinitis	3.19e-05	0.000129	CcSEcCtD
Paroxetine—Pruritus—Betamethasone—allergic rhinitis	3.17e-05	0.000128	CcSEcCtD
Paroxetine—Pruritus—Dexamethasone—allergic rhinitis	3.17e-05	0.000128	CcSEcCtD
Paroxetine—CHRM4—Signaling Pathways—CYSLTR1—allergic rhinitis	3.16e-05	0.00115	CbGpPWpGaD
Paroxetine—TACR1—Signaling Pathways—SMAD3—allergic rhinitis	3.16e-05	0.00115	CbGpPWpGaD
Paroxetine—Vomiting—Triamcinolone—allergic rhinitis	3.14e-05	0.000127	CcSEcCtD
Paroxetine—Vomiting—Methylprednisolone—allergic rhinitis	3.13e-05	0.000126	CcSEcCtD
Paroxetine—Nausea—Hydrocortisone—allergic rhinitis	3.12e-05	0.000126	CcSEcCtD
Paroxetine—Rash—Triamcinolone—allergic rhinitis	3.11e-05	0.000125	CcSEcCtD
Paroxetine—Dermatitis—Triamcinolone—allergic rhinitis	3.11e-05	0.000125	CcSEcCtD
Paroxetine—Rash—Methylprednisolone—allergic rhinitis	3.11e-05	0.000125	CcSEcCtD
Paroxetine—Dermatitis—Methylprednisolone—allergic rhinitis	3.1e-05	0.000125	CcSEcCtD
Paroxetine—Headache—Triamcinolone—allergic rhinitis	3.09e-05	0.000125	CcSEcCtD
Paroxetine—Headache—Methylprednisolone—allergic rhinitis	3.09e-05	0.000124	CcSEcCtD
Paroxetine—Diarrhoea—Dexamethasone—allergic rhinitis	3.07e-05	0.000124	CcSEcCtD
Paroxetine—Diarrhoea—Betamethasone—allergic rhinitis	3.07e-05	0.000124	CcSEcCtD
Paroxetine—CHRM4—Signaling Pathways—CCL11—allergic rhinitis	3.05e-05	0.00111	CbGpPWpGaD
Paroxetine—CHRM5—Signaling Pathways—CYSLTR1—allergic rhinitis	3.03e-05	0.0011	CbGpPWpGaD
Paroxetine—Dizziness—Dexamethasone—allergic rhinitis	2.96e-05	0.000119	CcSEcCtD
Paroxetine—Dizziness—Betamethasone—allergic rhinitis	2.96e-05	0.000119	CcSEcCtD
Paroxetine—Nausea—Triamcinolone—allergic rhinitis	2.93e-05	0.000118	CcSEcCtD
Paroxetine—Nausea—Methylprednisolone—allergic rhinitis	2.93e-05	0.000118	CcSEcCtD
Paroxetine—CHRM5—Signaling Pathways—CCL11—allergic rhinitis	2.92e-05	0.00106	CbGpPWpGaD
Paroxetine—Vomiting—Betamethasone—allergic rhinitis	2.85e-05	0.000115	CcSEcCtD
Paroxetine—Vomiting—Dexamethasone—allergic rhinitis	2.85e-05	0.000115	CcSEcCtD
Paroxetine—Rash—Dexamethasone—allergic rhinitis	2.83e-05	0.000114	CcSEcCtD
Paroxetine—Rash—Betamethasone—allergic rhinitis	2.83e-05	0.000114	CcSEcCtD
Paroxetine—Dermatitis—Dexamethasone—allergic rhinitis	2.82e-05	0.000114	CcSEcCtD
Paroxetine—Dermatitis—Betamethasone—allergic rhinitis	2.82e-05	0.000114	CcSEcCtD
Paroxetine—Headache—Dexamethasone—allergic rhinitis	2.81e-05	0.000113	CcSEcCtD
Paroxetine—Headache—Betamethasone—allergic rhinitis	2.81e-05	0.000113	CcSEcCtD
Paroxetine—HTR2A—GPCR downstream signaling—TAC1—allergic rhinitis	2.8e-05	0.00102	CbGpPWpGaD
Paroxetine—CHRM1—GPCR downstream signaling—TAC1—allergic rhinitis	2.79e-05	0.00101	CbGpPWpGaD
Paroxetine—CHRM3—GPCR downstream signaling—TAC1—allergic rhinitis	2.78e-05	0.00101	CbGpPWpGaD
Paroxetine—CHRM2—GPCR downstream signaling—TAC1—allergic rhinitis	2.75e-05	0.000999	CbGpPWpGaD
Paroxetine—HTR2A—Signaling Pathways—PTGDR2—allergic rhinitis	2.73e-05	0.000991	CbGpPWpGaD
Paroxetine—CHRM1—Signaling Pathways—PTGDR2—allergic rhinitis	2.72e-05	0.000986	CbGpPWpGaD
Paroxetine—CHRM3—Signaling Pathways—PTGDR2—allergic rhinitis	2.71e-05	0.000983	CbGpPWpGaD
Paroxetine—CHRM2—Signaling Pathways—PTGDR2—allergic rhinitis	2.68e-05	0.000973	CbGpPWpGaD
Paroxetine—Nausea—Betamethasone—allergic rhinitis	2.66e-05	0.000107	CcSEcCtD
Paroxetine—Nausea—Dexamethasone—allergic rhinitis	2.66e-05	0.000107	CcSEcCtD
Paroxetine—HTR2A—GPCR downstream signaling—IL5—allergic rhinitis	2.6e-05	0.000946	CbGpPWpGaD
Paroxetine—CHRM1—GPCR downstream signaling—IL5—allergic rhinitis	2.59e-05	0.000941	CbGpPWpGaD
Paroxetine—CHRM3—GPCR downstream signaling—IL5—allergic rhinitis	2.58e-05	0.000938	CbGpPWpGaD
Paroxetine—CHRM2—GPCR downstream signaling—IL5—allergic rhinitis	2.56e-05	0.000929	CbGpPWpGaD
Paroxetine—HTR2A—Signaling by GPCR—TAC1—allergic rhinitis	2.54e-05	0.000924	CbGpPWpGaD
Paroxetine—CHRM1—Signaling by GPCR—TAC1—allergic rhinitis	2.53e-05	0.000919	CbGpPWpGaD
Paroxetine—CHRM3—Signaling by GPCR—TAC1—allergic rhinitis	2.52e-05	0.000916	CbGpPWpGaD
Paroxetine—CHRM2—Signaling by GPCR—TAC1—allergic rhinitis	2.5e-05	0.000907	CbGpPWpGaD
Paroxetine—HTR2A—Signaling by GPCR—IL5—allergic rhinitis	2.37e-05	0.000859	CbGpPWpGaD
Paroxetine—CHRM1—Signaling by GPCR—IL5—allergic rhinitis	2.35e-05	0.000855	CbGpPWpGaD
Paroxetine—CHRM3—Signaling by GPCR—IL5—allergic rhinitis	2.35e-05	0.000852	CbGpPWpGaD
Paroxetine—CHRM2—Signaling by GPCR—IL5—allergic rhinitis	2.32e-05	0.000844	CbGpPWpGaD
Paroxetine—CHRM4—Signaling Pathways—TAC1—allergic rhinitis	2.22e-05	0.000805	CbGpPWpGaD
Paroxetine—HTR2A—Signaling Pathways—CYSLTR1—allergic rhinitis	2.14e-05	0.000778	CbGpPWpGaD
Paroxetine—CHRM1—Signaling Pathways—CYSLTR1—allergic rhinitis	2.13e-05	0.000774	CbGpPWpGaD
Paroxetine—CHRM3—Signaling Pathways—CYSLTR1—allergic rhinitis	2.12e-05	0.000771	CbGpPWpGaD
Paroxetine—CHRM5—Signaling Pathways—TAC1—allergic rhinitis	2.12e-05	0.000771	CbGpPWpGaD
Paroxetine—CHRM2—Signaling Pathways—CYSLTR1—allergic rhinitis	2.1e-05	0.000764	CbGpPWpGaD
Paroxetine—HTR2A—Signaling Pathways—CCL11—allergic rhinitis	2.07e-05	0.000751	CbGpPWpGaD
Paroxetine—CHRM4—Signaling Pathways—IL5—allergic rhinitis	2.06e-05	0.000749	CbGpPWpGaD
Paroxetine—CHRM1—Signaling Pathways—CCL11—allergic rhinitis	2.06e-05	0.000747	CbGpPWpGaD
Paroxetine—CHRM3—Signaling Pathways—CCL11—allergic rhinitis	2.05e-05	0.000745	CbGpPWpGaD
Paroxetine—CHRM2—Signaling Pathways—CCL11—allergic rhinitis	2.03e-05	0.000738	CbGpPWpGaD
Paroxetine—ABCB1—Integrated Pancreatic Cancer Pathway—NFKB1—allergic rhinitis	2.02e-05	0.000735	CbGpPWpGaD
Paroxetine—CHRM5—Signaling Pathways—IL5—allergic rhinitis	1.97e-05	0.000717	CbGpPWpGaD
Paroxetine—ABCB1—Integrated Pancreatic Cancer Pathway—TGFB1—allergic rhinitis	1.68e-05	0.000612	CbGpPWpGaD
Paroxetine—TACR1—Signaling Pathways—NFKB1—allergic rhinitis	1.61e-05	0.000583	CbGpPWpGaD
Paroxetine—HTR2A—Signaling Pathways—TAC1—allergic rhinitis	1.5e-05	0.000546	CbGpPWpGaD
Paroxetine—CHRM1—Signaling Pathways—TAC1—allergic rhinitis	1.5e-05	0.000543	CbGpPWpGaD
Paroxetine—CHRM3—Signaling Pathways—TAC1—allergic rhinitis	1.49e-05	0.000541	CbGpPWpGaD
Paroxetine—CHRM2—Signaling Pathways—TAC1—allergic rhinitis	1.48e-05	0.000536	CbGpPWpGaD
Paroxetine—CHRM4—Signaling Pathways—SMAD3—allergic rhinitis	1.45e-05	0.000527	CbGpPWpGaD
Paroxetine—HTR2A—Signaling Pathways—IL5—allergic rhinitis	1.4e-05	0.000508	CbGpPWpGaD
Paroxetine—CHRM1—Signaling Pathways—IL5—allergic rhinitis	1.39e-05	0.000505	CbGpPWpGaD
Paroxetine—CHRM5—Signaling Pathways—SMAD3—allergic rhinitis	1.39e-05	0.000505	CbGpPWpGaD
Paroxetine—CHRM3—Signaling Pathways—IL5—allergic rhinitis	1.39e-05	0.000503	CbGpPWpGaD
Paroxetine—CHRM2—Signaling Pathways—IL5—allergic rhinitis	1.37e-05	0.000498	CbGpPWpGaD
Paroxetine—TACR1—Signaling Pathways—TGFB1—allergic rhinitis	1.34e-05	0.000486	CbGpPWpGaD
Paroxetine—HTR2A—Signaling Pathways—SMAD3—allergic rhinitis	9.83e-06	0.000357	CbGpPWpGaD
Paroxetine—CHRM1—Signaling Pathways—SMAD3—allergic rhinitis	9.78e-06	0.000355	CbGpPWpGaD
Paroxetine—CHRM3—Signaling Pathways—SMAD3—allergic rhinitis	9.75e-06	0.000354	CbGpPWpGaD
Paroxetine—CHRM2—Signaling Pathways—SMAD3—allergic rhinitis	9.66e-06	0.000351	CbGpPWpGaD
Paroxetine—CHRM4—Signaling Pathways—NFKB1—allergic rhinitis	7.37e-06	0.000268	CbGpPWpGaD
Paroxetine—CHRM5—Signaling Pathways—NFKB1—allergic rhinitis	7.06e-06	0.000256	CbGpPWpGaD
Paroxetine—CHRM4—Signaling Pathways—TGFB1—allergic rhinitis	6.14e-06	0.000223	CbGpPWpGaD
Paroxetine—CHRM5—Signaling Pathways—TGFB1—allergic rhinitis	5.88e-06	0.000214	CbGpPWpGaD
Paroxetine—HTR2A—Signaling Pathways—NFKB1—allergic rhinitis	5e-06	0.000182	CbGpPWpGaD
Paroxetine—CHRM1—Signaling Pathways—NFKB1—allergic rhinitis	4.97e-06	0.000181	CbGpPWpGaD
Paroxetine—CHRM3—Signaling Pathways—NFKB1—allergic rhinitis	4.96e-06	0.00018	CbGpPWpGaD
Paroxetine—CHRM2—Signaling Pathways—NFKB1—allergic rhinitis	4.91e-06	0.000178	CbGpPWpGaD
Paroxetine—HTR2A—Signaling Pathways—TGFB1—allergic rhinitis	4.16e-06	0.000151	CbGpPWpGaD
Paroxetine—CHRM1—Signaling Pathways—TGFB1—allergic rhinitis	4.14e-06	0.00015	CbGpPWpGaD
Paroxetine—CHRM3—Signaling Pathways—TGFB1—allergic rhinitis	4.13e-06	0.00015	CbGpPWpGaD
Paroxetine—CHRM2—Signaling Pathways—TGFB1—allergic rhinitis	4.09e-06	0.000149	CbGpPWpGaD
